<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2015-12-03" updated="2019-12-02">
  <drugbank-id primary="true">DB11180</drugbank-id>
  <name>Tetrofosmin</name>
  <description>Tetrofosmin was developed to overcome the non-target uptake of radioligands by the generation of hetero-atomic compounds. It presents a molecular formula of 1,2-bis(bis(2-ethoxyethyl)phosphino)ethane. Tetrofosmin is part of the group of diphosphines. The sell of tetrofosmin in a freeze-dried kit is FDA approved and it is always accompanied by technetium Tc-99m as a radiopharmaceutical.[A7788]</description>
  <cas-number>127502-06-1</cas-number>
  <unii>3J0KPB596Q</unii>
  <average-mass>382.462</average-mass>
  <monoisotopic-mass>382.240183764</monoisotopic-mass>
  <state>liquid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A7788</ref-id>
        <pubmed-id>8429340</pubmed-id>
        <citation>Kelly JD, Forster AM, Higley B, Archer CM, Booker FS, Canning LR, Chiu KW, Edwards B, Gill HK, McPartlin M, et al.: Technetium-99m-tetrofosmin as a new radiopharmaceutical for myocardial perfusion imaging. J Nucl Med. 1993 Feb;34(2):222-7.</citation>
      </article>
      <article>
        <ref-id>A32342</ref-id>
        <pubmed-id>8326381</pubmed-id>
        <citation>Jain D, Wackers FJ, Mattera J, McMahon M, Sinusas AJ, Zaret BL: Biokinetics of technetium-99m-tetrofosmin: myocardial perfusion imaging agent: implications for a one-day imaging protocol. J Nucl Med. 1993 Aug;34(8):1254-9.</citation>
      </article>
    </articles>
    <textbooks>
      <textbook>
        <ref-id>T82</ref-id>
        <isbn/>
        <citation>Jadvar H. (2014). Cancer theranostics. Academic press.</citation>
      </textbook>
    </textbooks>
    <links>
      <link>
        <ref-id>L2001</ref-id>
        <title>Tetrofosmin monograph</title>
        <url>https://www3.gehealthcare.com/~/media/documents/us-global/products/nuclear-imaging-agents_non-gatekeeper/clinical%20product%20info/myoview/gehealthcare_myoview-30ml-prescribing-information.pdf?Parent=%7B8676C68D-813E-43A2-BBB8-036FD061A97B%7D</url>
      </link>
    </links>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Tetrofosmin is indicated to be used as a complex with technetium Tc-99m for scintigraphic imaging of the myocardium following separate administrations under exercise and/or resting conditions. It helps in the delineation of regions of reversible myocardial ischemia in absence of infarcted myocardium.[L2001]&#13;
&#13;
This complex is also used for scintigraphic imaging of the myocardium to identify changes in perfusion induced by pharmacologic stress in patients with known or suspected coronary artery disease.[L2001]&#13;
&#13;
This complex is indicated for the assessment of left ventricular function in patients evaluated for heart disease.[L2001]</indication>
  <pharmacodynamics>Refer to [DB09160]</pharmacodynamics>
  <mechanism-of-action>Tetrofosmin normal biodistribution makes it suitable to be used as a myocardial agent as it is uptaken by the myocardial tissue and it presents a very low redistribution after 3-4 hours of administration.[A32342] After distribution, tetrofosmin is a lipophilic cationic agent which is passively diffused and accumulated in viable myocardial tissue.[T82]</mechanism-of-action>
  <toxicity>The toxicity of tetrofosmin as an individual agent has not been studied.</toxicity>
  <metabolism>This pharmacokinetic property has not been fully studied.</metabolism>
  <absorption>After intravenous administration, tetrofosmin is rapidly cleared from the blood and taken up by the heart, skeletal muscle, liver, spleen and kidneys.[A32342]</absorption>
  <half-life>Refer to [DB09160]</half-life>
  <protein-binding>Refer to [DB09160]</protein-binding>
  <route-of-elimination>Refer to [DB09160]</route-of-elimination>
  <volume-of-distribution>This pharmacokinetic property has not been fully studied.</volume-of-distribution>
  <clearance>Refer to [DB09160]</clearance>
  <classification>
    <description>This compound belongs to the class of organic compounds known as organic phosphines and derivatives. These are organic compounds containing a phosphine derivative, with the general formula B1P(R2)R3 (R1-R3=alkyl, aryl).</description>
    <direct-parent>Organic phosphines and derivatives</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Organophosphorus compounds</superclass>
    <class>Organic phosphines and derivatives</class>
    <subclass/>
    <alternative-parent>Dialkyl ethers</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <substituent>Aliphatic acyclic compound</substituent>
    <substituent>Dialkyl ether</substituent>
    <substituent>Ether</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Phosphine</substituent>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="english" coder="inn/usan">Tetrofosmin</synonym>
    <synonym language="spanish" coder="">Tetrofosmina</synonym>
  </synonyms>
  <products>
    <product>
      <name>Myoview</name>
      <labeller>Medi-Physics Inc. dba GE Healthcare</labeller>
      <ndc-id/>
      <ndc-product-code>17156-024</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-08-08</started-marketing-on>
      <ended-marketing-on>2017-05-31</ended-marketing-on>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>0.23 mg/1</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA020372</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Myoview</name>
      <labeller>Medi-Physics Inc. dba GE Healthcare</labeller>
      <ndc-id/>
      <ndc-product-code>17156-026</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-02-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>1.38 mg/1</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA020372</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tetrofosmin</name>
      <labeller>Anazao Health Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>51808-223</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-05-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>0.35 mg/1</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Tetrofosmin</name>
      <ingredients>Tetrofosmin</ingredients>
    </mixture>
    <mixture>
      <name>Myoview</name>
      <ingredients>Tetrofosmin</ingredients>
    </mixture>
    <mixture>
      <name>Myoview</name>
      <ingredients>Tetrofosmin</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories/>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Injection, powder, lyophilized, for solution</form>
      <route>Intravenous</route>
      <strength>0.23 mg/1</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, lyophilized, for solution</form>
      <route>Intravenous</route>
      <strength>1.38 mg/1</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, lyophilized, for solution</form>
      <route>Intravenous</route>
      <strength>0.35 mg/1</strength>
    </dosage>
  </dosages>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB11180.pdf?1522363490</fda-label>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB11180.pdf?1522698557</msds>
  <patents>
    <patent>
      <number>9549999</number>
      <country>United States</country>
      <approved>2017-01-24</approved>
      <expires>2030-03-10</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions/>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>3.85</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-5.8</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>6.64e-04 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>1.14</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>6,9-bis(2-ethoxyethyl)-3,12-dioxa-6,9-diphosphatetradecane</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>tetrofosmin</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>382.462</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>382.240183764</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>CCOCCP(CCOCC)CCP(CCOCC)CCOCC</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C18H40O4P2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C18H40O4P2/c1-5-19-9-13-23(14-10-20-6-2)17-18-24(15-11-21-7-3)16-12-22-8-4/h5-18H2,1-4H3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>QCWJONLQSHEGEJ-UHFFFAOYSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>36.92</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>115.73</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>45.62</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>19</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>8.3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Water Solubility</kind>
      <value>Soluble </value>
      <source>'MSDS'</source>
    </property>
    <property>
      <kind>Boiling Point</kind>
      <value>100ÂºC</value>
      <source>'MSDS'</source>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>135598</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>4274</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>347827934</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>4124</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Technetium_(99mTc)_tetrofosmin</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1615784</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>